Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03114319 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 227
- Enrollment target
NCT03114319 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 227 participants.
The verdict
NCT03114319, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 227 participants
- Enrollment target
Study Summary
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.
Interventions
- DRUG TNO155
- DRUG TNO155 in combination with EGF816 (nazartinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2017-05-26 |
| Est. Completion | 2025-07-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03114319
The ClinicalTrials.gov registry entry for NCT03114319 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TNO155 is the first listed.
NCT03114319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03114319 about?
NCT03114319 is a clinical study titled "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors". The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.
What is the current status of trial NCT03114319?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 227 participants. The study started on 2017-05-26. Estimated completion is 2025-07-04.
What interventions are being tested in trial NCT03114319?
The interventions under investigation include: TNO155 (DRUG), TNO155 in combination with EGF816 (nazartinib) (DRUG).
Who is sponsoring clinical trial NCT03114319?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.